• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Relay Therapeutics Inc.

    6/22/26 4:57:39 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RLAY alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001709772
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    RELAY THERAPEUTICS, INC.
    SEC File Number
    001-39385
    Address of Issuer
    60 Hampshire Street
    Cambridge
    MASSACHUSETTS
    02139
    Phone
    617-370-8837
    Name of Person for Whose Account the Securities are To Be Sold
    DONALD BERGSTROM
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    1106461757058.4819158616506/22/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/22/2026Exercise of Stock OptionsIssuerCheckbox not checked9345606/22/2026Cash
    Common12/26/2021Restricted Stock UnitsIssuerCheckbox not checked1719012/26/2021N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    DONALD A. BERGSTROM
    60 Hampshire Street
    Cambridge � MA � 02139
    Common04/28/2026149022037.10

    144: Remarks and Signature

    Remarks
    The securities to be sold were acquired upon the vesting of restricted stock units during the period of 12/26/2021 through 07/27/2023.
    Date of Notice
    06/22/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    10/30/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Donald Bergstrom

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $RLAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLAY

    DatePrice TargetRatingAnalyst
    1/26/2026$14.00Perform → Outperform
    Oppenheimer
    12/12/2025$13.00Equal Weight → Overweight
    Wells Fargo
    9/4/2025$15.00Buy
    Guggenheim
    4/17/2025$4.00Equal Weight
    Wells Fargo
    9/10/2024$20.00Buy
    Goldman
    9/10/2024Outperform → Perform
    Oppenheimer
    9/10/2024$10.60 → $16.00Hold → Buy
    Jefferies
    5/10/2024$15.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mazumdar Claire

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    6/10/26 4:30:11 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Murcko Mark

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    6/10/26 4:30:03 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Borisy Alexis

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    6/10/26 4:30:06 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Relay Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a new price target of $14.00

    1/26/26 8:32:07 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Relay Therapeutics from Equal Weight to Overweight and set a new price target of $13.00

    12/12/25 8:37:26 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim resumed coverage on Relay Therapeutics with a new price target

    Guggenheim resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $15.00

    9/4/25 9:07:32 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

    CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ETGoldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: https://

    5/27/26 4:05:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 milli

    5/20/26 8:21:22 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today that it has commenced an underwritten public offering of $175 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Relay Therapeutics. Jefferies, TD Cowen, Goldman Sachs & Co. LLC and Guggenhei

    5/19/26 4:03:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    SEC Filings

    View All

    SEC Form 144 filed by Relay Therapeutics Inc.

    144 - Relay Therapeutics, Inc. (0001812364) (Subject)

    6/22/26 4:57:39 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

    6/9/26 4:35:35 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Relay Therapeutics Inc.

    8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

    5/21/26 5:07:30 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Leadership Updates

    Live Leadership Updates

    View All

    Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

    CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

    6/11/25 4:05:00 PM ET
    $BCAX
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Section 32 Raises $740 Million Venture Fund

    SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

    11/4/21 8:14:00 AM ET
    $COIN
    $CRWD
    $EXAS
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology

    Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

    Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform. This press release

    10/14/21 8:00:00 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.

    SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

    11/14/24 1:22:38 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)

    SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

    2/14/24 4:20:24 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Relay Therapeutics Inc.

    SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)

    2/14/24 10:03:03 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Financials

    Live finance-specific insights

    View All

    Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

    Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported outcomes show 89% and 79% of patients achieved clinical improvement at week 12, respectively, and support the potential of zovegalisib to drive clinically meaningful benefit for patients Evaluation across a wide dose range confirms potential therapeutic window, with interim safety profile supportive of chronic dosing and no patients discontinuing treatment due to adverse events Expansion cohorts for adults and adolescents opened at 400mg once daily (QD) and 300mg BID;pediatric

    5/19/26 6:00:00 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

    FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced patients at ESMO TAT, demonstrating 11.1-month median PFS with similar efficacy in kinase and non-kinase mutations Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027 Initiated Phase 1/2 trial of RLY-8161, a NRAS-selective molecule, in patients with NRAS-mutant solid tumors Initial vascular anomalies clinical data conferenc

    5/5/26 4:05:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

    Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback Supply agreement in place with Pfizer to supply atirmociclib for the Phase 3 frontline trial Relay Therapeutics to host a conference call today, April 27, at 8:30am ET CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ

    4/27/26 6:00:00 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care